Composition, useful to treat or prevent viral infection, comprises a hexanucleotide as biological component and optionally a carrier, where the hexanucleotide arranged in specific direction against a protein-like biopolymer

Composition (I), comprises at least a hexanucleotide as a biologically effective component and optionally at least a carrier where the hexanucleotide is arranged in specific direction against a protein-like biopolymer. Independent claims are included for: (1) a procedure for the preparation of hexanucleotide specifically directed against protein-like biopolymer comprises: providing a first system, which comprises n different sequence hexanucleotide, where each hexanucleotide contains one or more hexanucleotide with same nucleotide sequence, each of the other different nucleotide sequence of the hexanucleotide differs and entire number of n is 2-4096; providing a second system, which comprises at least the protein-like biopolymer; and contacting the first system with the second system under conditions, which enables a goal specific hexanucleotide at the protein-like biopolymer, under development of a hexanucleotide/biopolymer complex; and (2) a kit comprising a hexanucleotide to reduce or completely inhibit the biological activity of the protein-like biopolymers. ACTIVITY : Virucide; Anti-HIV. MECHANISM OF ACTION : None given. Die vorliegende Erfindung betrifft eine pharmazeutische Zusammensetzung, enthaltend mindestens ein gegen ein proteinartiges Biopolymer zielspezifisch gerichtetes Hexanukleotid als pharmazeutisch aktiven Bestandteil, ein Verfahren zur Herstellung eines gegen ein proteinartiges Biopolymer zielspezifisch gerichteten Hexanukleotids, die Verwendung eines Hexanukleotids zur Behandlung oder Vorbeugung von Erkrankungen, beispielsweise viraler Infektionen bei Säugern, sowie einen Kit, enthaltend mindestens ein gegen ein proteinartiges Biopolymer zielspezifisch gerichtetes Hexanukleotid.